MetaVia cites preclinical study showing vanoglipel reduces liver fibrosis in MASH

• MetaVia highlighted a newly published peer-reviewed preclinical study supporting an anti-fibrotic effect for its GPR119 agonist vanoglipel in metabolic liver disease.
• Results were already presented via the journal publication, with findings indicating reduced liver scarring signals in laboratory models.
• The readout adds mechanistic support to a previously completed Phase 2a study in presumed MASH, which showed improvements in liver injury and fibrosis markers versus placebo.
• The company positioned the data as strengthening the case for vanoglipel as a potential standalone therapy or a combination option in MASH with fibrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605200800PR_NEWS_USPR_____NY63117) on May 20, 2026, and is solely responsible for the information contained therein.